Accordingly, to suppress wild-type B-Raf, we administered an oral dose of 32 mg/kg of BW/day vemurafenib; this dose was derived from the dose approved by the FDA for use in melanoma patients (https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf). This evidence concerns the gene BRAF and melanoma.